481
Participants
Start Date
February 9, 2024
Primary Completion Date
March 24, 2026
Study Completion Date
February 23, 2027
Dolutegravir
Dolutegravir will be administered once daily.
Lamivudine
Lamivudine will be administered once daily.
Bictegravir
Bictegravir will be administered once daily.
Emtricitabine
Emtricitabine will be administered once daily.
Tenofovir alafenamide
Tenofovir alafenamide will be administered once daily.
GSK Investigational Site, Dublin
GSK Investigational Site, Brussels
GSK Investigational Site, Antwerp
GSK Investigational Site, Hvidovre
GSK Investigational Site, Basel
GSK Investigational Site, Palma de Mallorca
GSK Investigational Site, Zurich
GSK Investigational Site, Ghent
GSK Investigational Site, Berlin
GSK Investigational Site, Hamburg
GSK Investigational Site, Bergamo
GSK Investigational Site, Pavia
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Marbella
GSK Investigational Site, Nîmes
GSK Investigational Site, Lyon
GSK Investigational Site, Haifa
GSK Investigational Site, Bordeaux
GSK Investigational Site, Bordeaux
GSK Investigational Site, Montpellier
GSK Investigational Site, La Laguna-Tenerife
GSK Investigational Site, Padua
GSK Investigational Site, Zapopan
GSK Investigational Site, Valencia
GSK Investigational Site, Cologne
GSK Investigational Site, Ramat Gan
GSK Investigational Site, Thessaloniki
GSK Investigational Site, Frankfurt
GSK Investigational Site, Tel Aviv
GSK Investigational Site, Bari
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Rehovot
GSK Investigational Site, München
GSK Investigational Site, Mérida
GSK Investigational Site, Ciudad Autonoma de Buenos Aire
GSK Investigational Site, Córdoba
GSK Investigational Site, Nice
GSK Investigational Site, Athens
GSK Investigational Site, Athens
GSK Investigational Site, Dublin
GSK Investigational Site, Sassari
GSK Investigational Site, Aichi
GSK Investigational Site, Osaka
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Bydgoszcz
GSK Investigational Site, Lodz
GSK Investigational Site, Wroclaw
GSK Investigational Site, Aveiro
GSK Investigational Site, Porto
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Elche Alicante
GSK Investigational Site, Palma de Mallorca
GSK Investigational Site, Stockholm
GSK Investigational Site, Glasgow
GSK Investigational Site, London
GSK Investigational Site, London
GSK Investigational Site, London
GSK Investigational Site, London
Lead Sponsor
ViiV Healthcare
INDUSTRY